ePrints

Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease

Lookup NU author(s): Dr Helen GriffinORCiD, Dr Eleri Williams, Professor Andrew Cant, Professor Sophie Hambleton

Downloads

• Accepted version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

Copyright © 2024 Massachusetts Medical Society. We discovered high-titer neutralizing autoantibodies against interleukin-10 in a child with infantile-onset inflammatory bowel disease (IBD), a phenocopy of inborn errors of interleukin-10 signaling. After B-cell-depletion therapy and an associated decrease in the anti-interleukin-10 titer, conventional IBD therapy could be withdrawn. A second child with neutralizing anti-interleukin-10 autoantibodies had a milder course of IBD and has been treated without B-cell depletion. We conclude that neutralizing anti-interleukin-10 autoantibodies may be a causative or modifying factor in IBD, with potential implications for therapy. (Funded by the National Institute for Health and Care Research and others.).

Publication metadata

Author(s): Griffin H, Ceron-Gutierrez L, Gharahdaghi N, Ebrahimi S, Davies S, Loo PS, Szabo A, Williams E, Mukhopadhyay A, McLoughlin L, Irwin S, Travis S, Klenerman P, Bunn S, Cant AJ, Hambleton S, Uhlig HH, Doffinger R

Publication type: Article

Publication status: Published

Journal: New England Journal of Medicine

Year: 2024

Volume: 391

Issue: 5

Pages: 434-441

Print publication date: 01/08/2024

Online publication date: 31/07/2024

Acceptance date: 02/04/2018

Date deposited: 11/09/2024

ISSN (print): 0028-4793

ISSN (electronic): 1533-4406

Publisher: Massachusetts Medical Society

URL: https://doi.org/10.1056/NEJMoa2312302

DOI: 10.1056/NEJMoa2312302

PubMed id: 39083772

Altmetrics

Funding

Share